Because prior reports have found that the KRAS-variant is rarely associated with premenopausal ovarian cancer (less then 52 years of age) [9], [14], we next evaluated the association of the KRAS-variant with age of ovarian cancer development in uninformative double primary patients. This evidence concerns the gene KRAS and ovarian carcinoma.